FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048657404> ?p ?o ?g. }

• W3048657404 endingPage "1158" @default.
• W3048657404 startingPage "1153" @default.
• W3048657404 abstract "Abstract Background Asthma is one of the most common chronic diseases worldwide and can often be controlled by existing treatments, but in the 5%‐10% of patients with severe asthma, control is frequently more challenging. The aim of this paper is to evaluate the adherence to preventer inhaler therapy in severe asthmatic patients receiving omalizumab, a recombinant humanized monoclonal anti‐IgE antibody indicated for moderate‐to‐severe asthma. Methods This study included 29 patients who were receiving omalizumab treatment as maintenance therapy. All patients completed the six question Turkish Modified Morisky Scale. In addition, patients were classified by adherence to their prescribed preventer therapy, based on pharmaceutical and medical device institution records from the preceding one year. Results Of the 29 enrolled patients, 24.1% had NSAID‐exacerbated respiratory disease; 75.9% were female and median age was 47.2 ± 12.99 years. Severe asthma patients demonstrated high levels of motivation (98.8%, n = 28) and knowledge (86.2%, n = 22) about asthma treatment. Nevertheless, the rate of nonadherence to preventer inhaler therapy was only 34.5% (n = 10). There were no significant differences among the characteristics of the patients that might affect the adherence to inhaler therapy. Conclusion In patients with severe asthma, suboptimal adherence to preventer inhaler therapy is common before and after omalizumab treatment. Although patients have high levels of motivation and knowledge about asthma treatment, adherence to inhaler preventer therapy declined after omalizumab therapy. Given these findings, it is important to decide whether preventer inhaler therapy should be continued as monotherapy or be discontinued inpatients exhibiting impaired adherence to biological agents, such as omalizumab." @default.
• W3048657404 created "2020-08-18" @default.
• W3048657404 creator A5006443771 @default.
• W3048657404 date "2020-09-10" @default.
• W3048657404 modified "2023-10-16" @default.
• W3048657404 title "Evaluating nonadherence to preventer inhaler therapy in severe asthmatic patients receiving omalizumab" @default.
• W3048657404 cites W2018827828 @default.
• W3048657404 cites W2030618731 @default.
• W3048657404 cites W2031756259 @default.
• W3048657404 cites W2044067055 @default.
• W3048657404 cites W2045685449 @default.
• W3048657404 cites W2094189191 @default.
• W3048657404 cites W2140647407 @default.
• W3048657404 cites W2511335722 @default.
• W3048657404 cites W2512776710 @default.
• W3048657404 cites W2742878664 @default.
• W3048657404 cites W2789690307 @default.
• W3048657404 cites W2803500312 @default.
• W3048657404 cites W2825384136 @default.
• W3048657404 doi "https://doi.org/10.1111/crj.13252" @default.
• W3048657404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32780932" @default.
• W3048657404 hasPublicationYear "2020" @default.
• W3048657404 type Work @default.
• W3048657404 sameAs 3048657404 @default.
• W3048657404 citedByCount "1" @default.
• W3048657404 countsByYear W30486574042021 @default.
• W3048657404 crossrefType "journal-article" @default.
• W3048657404 hasAuthorship W3048657404A5006443771 @default.
• W3048657404 hasConcept C126322002 @default.
• W3048657404 hasConcept C141105273 @default.
• W3048657404 hasConcept C159654299 @default.
• W3048657404 hasConcept C177713679 @default.
• W3048657404 hasConcept C203014093 @default.
• W3048657404 hasConcept C2776042228 @default.
• W3048657404 hasConcept C2777419714 @default.
• W3048657404 hasConcept C2778564945 @default.
• W3048657404 hasConcept C2780261241 @default.
• W3048657404 hasConcept C71924100 @default.
• W3048657404 hasConceptScore W3048657404C126322002 @default.
• W3048657404 hasConceptScore W3048657404C141105273 @default.
• W3048657404 hasConceptScore W3048657404C159654299 @default.
• W3048657404 hasConceptScore W3048657404C177713679 @default.
• W3048657404 hasConceptScore W3048657404C203014093 @default.
• W3048657404 hasConceptScore W3048657404C2776042228 @default.
• W3048657404 hasConceptScore W3048657404C2777419714 @default.
• W3048657404 hasConceptScore W3048657404C2778564945 @default.
• W3048657404 hasConceptScore W3048657404C2780261241 @default.
• W3048657404 hasConceptScore W3048657404C71924100 @default.
• W3048657404 hasIssue "12" @default.
• W3048657404 hasLocation W30486574041 @default.
• W3048657404 hasOpenAccess W3048657404 @default.
• W3048657404 hasPrimaryLocation W30486574041 @default.
• W3048657404 hasRelatedWork W1735104919 @default.
• W3048657404 hasRelatedWork W2062333112 @default.
• W3048657404 hasRelatedWork W2128822526 @default.
• W3048657404 hasRelatedWork W2185404129 @default.
• W3048657404 hasRelatedWork W2904406609 @default.
• W3048657404 hasRelatedWork W2905625004 @default.
• W3048657404 hasRelatedWork W2979090586 @default.
• W3048657404 hasRelatedWork W2992741235 @default.
• W3048657404 hasRelatedWork W3120454997 @default.
• W3048657404 hasRelatedWork W3111208606 @default.
• W3048657404 hasVolume "14" @default.
• W3048657404 isParatext "false" @default.
• W3048657404 isRetracted "false" @default.
• W3048657404 magId "3048657404" @default.
• W3048657404 workType "article" @default.